{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:57:04Z","timestamp":1793336224227,"version":"4.5.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40263-023-01044-1","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T14:02:28Z","timestamp":1700834548000},"page":"1027-1063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-3528","authenticated-orcid":false,"given":"Niloufar","family":"Pouyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1289-1953","authenticated-orcid":false,"given":"Farnaz","family":"Younesi Sisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-8879","authenticated-orcid":false,"given":"Alireza","family":"Kargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1313-2208","authenticated-orcid":false,"given":"Milan","family":"Scheidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3530-4544","authenticated-orcid":false,"given":"Jonathan D.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748\u201351. https:\/\/doi.org\/10.1176\/appi.ajp.2010.09091379.","journal-title":"Am J Psychiatry"},{"key":"1044_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/psyp.12518","volume":"53","author":"MJ Kozak","year":"2016","unstructured":"Kozak MJ, Cuthbert BN. The NIMH research domain criteria initiative: background, issues, and pragmatics. Psychophysiology. 2016;53:286\u201397. https:\/\/doi.org\/10.1111\/psyp.12518.","journal-title":"Psychophysiology"},{"key":"1044_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1017\/S095457940505039X","volume":"17","author":"EE Forbes","year":"2005","unstructured":"Forbes EE, Dahl RE. Neural systems of positive affect: Relevance to understanding child and adolescent depression? Dev Psychopathol. 2005;17:827\u201350. https:\/\/doi.org\/10.1017\/S095457940505039X.","journal-title":"Dev Psychopathol"},{"key":"1044_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/da.22593","volume":"34","author":"CT Taylor","year":"2017","unstructured":"Taylor CT, Lyubomirsky S, Stein MB. Upregulating the positive affect system in anxiety and depression: outcomes of a positive activity intervention. Depress Anxiety. 2017;34:267\u201380. https:\/\/doi.org\/10.1002\/da.22593.","journal-title":"Depress Anxiety"},{"key":"1044_CR5","unstructured":"Reward Responsiveness. National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/reward-responsiveness. Accessed 15 Mar 2023."},{"key":"1044_CR6","unstructured":"Reward Learning. National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/reward-learning. Accessed 15 Mar 2023."},{"key":"1044_CR7","unstructured":"Reward Valuation. National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/reward-valuation. Accessed 15 Mar 2023"},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaac.2012.01.011","volume":"51","author":"DL McMakin","year":"2012","unstructured":"McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012;51:404\u201311. https:\/\/doi.org\/10.1016\/j.jaac.2012.01.011.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1044_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1017\/S0033291711001905","volume":"42","author":"R Uher","year":"2012","unstructured":"Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med. 2012;42:967\u201380. https:\/\/doi.org\/10.1017\/S0033291711001905.","journal-title":"Psychol Med"},{"key":"1044_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7.","journal-title":"Lancet Psychiatry"},{"key":"1044_CR11","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology. 2022;47:1854\u201362. https:\/\/doi.org\/10.1038\/s41386-022-01344-y.","journal-title":"Neuropsychopharmacology"},{"key":"1044_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.","journal-title":"Pharmacol Rev"},{"key":"1044_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611\u201324. https:\/\/doi.org\/10.1038\/s41583-020-0367-2.","journal-title":"Nat Rev Neurosci"},{"key":"1044_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","volume":"27","author":"BT Anderson","year":"2020","unstructured":"Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27: 100538. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100538.","journal-title":"EClinicalMedicine"},{"key":"1044_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289\u201399. https:\/\/doi.org\/10.1177\/0269881114565144.","journal-title":"J Psychopharmacol"},{"key":"1044_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397. https:\/\/doi.org\/10.1177\/0269881116675513.","journal-title":"J Psychopharmacol"},{"key":"1044_CR17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29167","volume":"14","author":"JS Kurtz","year":"2022","unstructured":"Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, et al. The use of psychedelics in the treatment of medical conditions: an analysis of currently registered psychedelics studies in the American Drug Trial Registry. Cureus. 2022;14: e29167. https:\/\/doi.org\/10.7759\/cureus.29167.","journal-title":"Cureus"},{"key":"1044_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00944-y","author":"N Pouyan","year":"2022","unstructured":"Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, et al. A research domain criteria (RDoC)-guided dashboard to review psilocybin target domains: a systematic review. CNS Drugs. 2022. https:\/\/doi.org\/10.1007\/s40263-022-00944-y.","journal-title":"CNS Drugs"},{"key":"1044_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","volume":"142","author":"SJ Belouin","year":"2018","unstructured":"Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. Neuropharmacology. 2018;142:7\u201319. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.018.","journal-title":"Neuropharmacology"},{"key":"1044_CR20","unstructured":"OHAT N. OHAT risk of bias rating tool for human and animal studies. US Department of Health and Human Services 2015."},{"key":"1044_CR21","unstructured":"PANAS (state version). National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/units\/self-reports\/151098. Accessed 21 Nov 2022."},{"key":"1044_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1037\/0022-3514.54.6.1063","volume":"54","author":"D Watson","year":"1988","unstructured":"Watson D. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063. https:\/\/doi.org\/10.1037\/0022-3514.54.6.1063.","journal-title":"J Pers Soc Psychol"},{"key":"1044_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/wps.20087","volume":"13","author":"BN Cuthbert","year":"2014","unstructured":"Cuthbert BN. The RDoC framework: facilitating transition from ICD\/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13:28\u201335. https:\/\/doi.org\/10.1002\/wps.20087.","journal-title":"World Psychiatry"},{"key":"1044_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","volume":"27","author":"KH Preller","year":"2017","unstructured":"Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stampfli P, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27:451\u20137. https:\/\/doi.org\/10.1016\/j.cub.2016.12.030.","journal-title":"Curr Biol"},{"key":"1044_CR25","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1523\/JNEUROSCI.1939-17.2018","volume":"38","author":"KH Preller","year":"2018","unstructured":"Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX. Role of the 5-HT2A receptor in self- and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study. J Neurosci. 2018;38:3603\u201311. https:\/\/doi.org\/10.1523\/JNEUROSCI.1939-17.2018.","journal-title":"J Neurosci"},{"key":"1044_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiat. 2019;86:792\u2013800. https:\/\/doi.org\/10.1016\/j.biopsych.2019.05.019.","journal-title":"Biol Psychiat"},{"key":"1044_CR27","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1038\/s41598-020-68899-y","volume":"10","author":"P Duerler","year":"2020","unstructured":"Duerler P, Schilbach L, St\u00e4mpfli P, Vollenweider FX, Preller KH. LSD-induced increases in social adaptation to opinions similar to one\u2019s own are associated with stimulation of serotonin receptors. Sci Rep. 2020;10:12181. https:\/\/doi.org\/10.1038\/s41598-020-68899-y.","journal-title":"Sci Rep"},{"key":"1044_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13143","author":"H de Wit","year":"2022","unstructured":"de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: a placebo-controlled, dose-response study. Addict Biol. 2022. https:\/\/doi.org\/10.1111\/adb.13143.","journal-title":"Addict Biol"},{"key":"1044_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/09637214211051363","volume":"31","author":"BN Cuthbert","year":"2022","unstructured":"Cuthbert BN. Research domain criteria (RDoC): progress and potential. Curr Dir Psychol Sci. 2022;31:107\u201314. https:\/\/doi.org\/10.1177\/09637214211051363.","journal-title":"Curr Dir Psychol Sci"},{"key":"1044_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31:80\u20134. https:\/\/doi.org\/10.1055\/s-2007-979351.","journal-title":"Pharmacopsychiatry"},{"key":"1044_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE. 2010;5: e12412. https:\/\/doi.org\/10.1371\/journal.pone.0012412.","journal-title":"PLoS ONE"},{"key":"1044_CR32","doi-asserted-by":"publisher","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187:268\u201383. https:\/\/doi.org\/10.1007\/s00213-006-0457-5(discussion 284\u201392).","DOI":"10.1007\/s00213-006-0457-5"},{"key":"1044_CR33","unstructured":"Janke W, Debus G. Die Eigenschaftsw\u00f6rterliste: EWL. Verlag f\u00fcr Psychologie CJ Hogrefe; 1978."},{"key":"1044_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","volume":"51","author":"KA Maclean","year":"2012","unstructured":"Maclean KA, Leoutsakos JM, Johnson MW, Griffiths RR. Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig. 2012;51:721\u201337. https:\/\/doi.org\/10.1111\/j.1468-5906.2012.01685.x.","journal-title":"J Sci Study Relig"},{"key":"1044_CR35","unstructured":"McNair DM, Lorr M, Droppleman LF. Manual profile of mood states 1971."},{"key":"1044_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00213-012-2954-z","volume":"227","author":"ME Morean","year":"2013","unstructured":"Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O\u2019Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology. 2013;227:177\u201392. https:\/\/doi.org\/10.1007\/s00213-012-2954-z.","journal-title":"Psychopharmacology"},{"key":"1044_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1037\/\/0278-6133.4.3.219","volume":"4","author":"MF Scheier","year":"1985","unstructured":"Scheier MF, Carver CS. Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol. 1985;4:219\u201347. https:\/\/doi.org\/10.1037\/\/0278-6133.4.3.219.","journal-title":"Health Psychol"},{"key":"1044_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0896-6273(02)00963-7","volume":"36","author":"P Dayan","year":"2002","unstructured":"Dayan P, Balleine BW. Reward, motivation, and reinforcement learning. Neuron. 2002;36:285\u201398. https:\/\/doi.org\/10.1016\/S0896-6273(02)00963-7.","journal-title":"Neuron"},{"key":"1044_CR39","unstructured":"Serotonin. National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/units\/molecules\/149897. Accessed 9 Oct 2023."},{"key":"1044_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/0269881120959604","volume":"35","author":"Y Schmid","year":"2021","unstructured":"Schmid Y, Gasser P, Oehen P, Liechti ME. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol. 2021;35:362\u201374. https:\/\/doi.org\/10.1177\/0269881120959604.","journal-title":"J Psychopharmacol"},{"key":"1044_CR41","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","volume":"56","author":"PC Dolder","year":"2017","unstructured":"Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet. 2017;56:1219\u201330. https:\/\/doi.org\/10.1007\/s40262-017-0513-9.","journal-title":"Clin Pharmacokinet"},{"key":"1044_CR42","doi-asserted-by":"publisher","first-page":"pyv072","DOI":"10.1093\/ijnp\/pyv072","volume":"19","author":"PC Dolder","year":"2015","unstructured":"Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol. 2015;19:pyv072. https:\/\/doi.org\/10.1093\/ijnp\/pyv072.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1044_CR43","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, M\u00fcller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638\u201346. https:\/\/doi.org\/10.1038\/npp.2016.82.","journal-title":"Neuropsychopharmacology"},{"key":"1044_CR44","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-016-4453-0","volume":"234","author":"ME Liechti","year":"2017","unstructured":"Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans UR -:\/\/WOS:000400855400014. Psychopharmacology. 2017;234:1499\u2013510. https:\/\/doi.org\/10.1007\/s00213-016-4453-0.","journal-title":"Psychopharmacology"},{"key":"1044_CR45","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F, Ley L, M\u00fcller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180\u20137. https:\/\/doi.org\/10.1038\/s41386-022-01297-2.","journal-title":"Neuropsychopharmacology"},{"key":"1044_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00814","author":"R Kraehenmann","year":"2017","unstructured":"Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, et al. LSD increases primary process thinking via serotonin 2A receptor activation. Front Pharmacol. 2017. https:\/\/doi.org\/10.3389\/fphar.2017.00814.","journal-title":"Front Pharmacol"},{"key":"1044_CR47","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1017\/S0033291719002393","volume":"50","author":"T Pokorny","year":"2020","unstructured":"Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med. 2020;50:2255\u201364. https:\/\/doi.org\/10.1017\/S0033291719002393.","journal-title":"Psychol Med"},{"key":"1044_CR48","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082","author":"KH Preller","year":"2018","unstructured":"Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stampfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018. https:\/\/doi.org\/10.7554\/eLife.35082.","journal-title":"Elife"},{"key":"1044_CR49","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291722002963","author":"JW Kanen","year":"2022","unstructured":"Kanen JW, Luo Q, Rostami Kandroodi M, Cardinal RN, Robbins TW, Nutt DJ, et al. Effect of lysergic acid diethylamide (lsd) on reinforcement learning in humans. Psychol Med. 2022. https:\/\/doi.org\/10.1017\/S0033291722002963.","journal-title":"Psychol Med"},{"key":"1044_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0893-133X(98)00091-8","volume":"20","author":"RD Rogers","year":"1999","unstructured":"Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, et al. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology. 1999;20:322\u201339. https:\/\/doi.org\/10.1016\/S0893-133X(98)00091-8.","journal-title":"Neuropsychopharmacology"},{"key":"1044_CR51","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. PNAS. 2016;113:4853\u20138.","journal-title":"PNAS"},{"key":"1044_CR52","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1523\/JNEUROSCI.22-11-04563.2002","volume":"22","author":"R Cools","year":"2002","unstructured":"Cools R, Clark L, Owen AM, Robbins TW. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci. 2002;22:4563\u20137. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-11-04563.2002.","journal-title":"J Neurosci"},{"key":"1044_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bpsc.2019.12.007","volume":"5","author":"AK Bershad","year":"2020","unstructured":"Bershad AK, Preller KH, Lee R, Keedy S, Wren-Jarvis J, Bremmer MP, et al. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity UR -:\/\/WOS:000523693100012. Biol Psychiat-Cogn N. 2020;5:461\u20137. https:\/\/doi.org\/10.1016\/j.bpsc.2019.12.007.","journal-title":"Biol Psychiat-Cogn N"},{"key":"1044_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117653","volume":"227","author":"AI Luppi","year":"2021","unstructured":"Luppi AI, Carhart-Harris RL, Roseman L, Pappas I, Menon DK, Stamatakis EA. LSD alters dynamic integration and segregation in the human brain. Neuroimage. 2021;227: 117653. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.117653.","journal-title":"Neuroimage"},{"key":"1044_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","volume":"4","author":"NRPW Hutten","year":"2021","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, et al. Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol Transl Sci. 2021;4:461\u20136. https:\/\/doi.org\/10.1021\/acsptsci.0c00099.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1044_CR56","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00213-021-05991-9","volume":"239","author":"CH Murray","year":"2022","unstructured":"Murray CH, Tare I, Perry CM, Malina M, Lee R, de Wit H. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology. 2022;239:1735\u201347. https:\/\/doi.org\/10.1007\/s00213-021-05991-9.","journal-title":"Psychopharmacology"},{"key":"1044_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","volume":"41","author":"NRPW Hutten","year":"2020","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, et al. Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study UR -:\/\/WOS:000596581200008. Eur Neuropsychopharm. 2020;41:81\u201391. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.10.002.","journal-title":"Eur Neuropsychopharm"},{"key":"1044_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41386-022-01479-y","volume":"48","author":"J Glazer","year":"2022","unstructured":"Glazer J, Murray CH, Nusslock R, Lee R, de Wit H. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology. 2022;48:418\u201326. https:\/\/doi.org\/10.1038\/s41386-022-01479-y.","journal-title":"Neuropsychopharmacology"},{"key":"1044_CR59","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.neuropharm.2011.02.006","volume":"61","author":"D Marona-Lewicka","year":"2011","unstructured":"Marona-Lewicka D, Nichols CD, Nichols DE. An animal model of schizophrenia based on chronic LSD administration: Old idea, new results. Neuropharmacology. 2011;61:503\u201312. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.02.006.","journal-title":"Neuropharmacology"},{"key":"1044_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0091-3057(97)00391-2","volume":"59","author":"SM Meehan","year":"1998","unstructured":"Meehan SM, Schechter MD. LSD produces conditioned place preference in male but not female fawn hooded rats. Pharmacol Biochem Behav. 1998;59:105\u20138. https:\/\/doi.org\/10.1016\/S0091-3057(97)00391-2.","journal-title":"Pharmacol Biochem Behav"},{"key":"1044_CR61","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1037\/0735-7044.110.3.503","volume":"110","author":"LA Parker","year":"1996","unstructured":"Parker LA. LSD produces place preference and flavor avoidance but does not produce flavor aversion in rats. Behav Neurosci. 1996;110:503\u20138. https:\/\/doi.org\/10.1037\/0735-7044.110.3.503.","journal-title":"Behav Neurosci"},{"key":"1044_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00994","author":"K Alper","year":"2018","unstructured":"Alper K, Dong B, Shah R, Sershen H, Vinod KY. LSD administered as a single dose reduces alcohol consumption in C57BL\/6J mice. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.00994.","journal-title":"Front Pharmacol"},{"key":"1044_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.602770","author":"LV Elsila","year":"2020","unstructured":"Elsila LV, Korhonen N, Hyytia P, Korpi ER. Acute lysergic acid diethylamide does not influence reward-driven decision making of C57BL\/6 mice in the Iowa gambling task. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.602770.","journal-title":"Front Pharmacol"},{"key":"1044_CR64","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1177\/02698811221104641","volume":"36","author":"LV Elsil\u00e4","year":"2022","unstructured":"Elsil\u00e4 LV, Harkki J, Enberg E, Martti A, Linden A-M, Korpi ER. Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL\/6 mice. J Psychopharmacol. 2022;36:860\u201374. https:\/\/doi.org\/10.1177\/02698811221104641.","journal-title":"J Psychopharmacol"},{"key":"1044_CR65","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","volume":"11","author":"M Hibicke","year":"2020","unstructured":"Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864\u201371. https:\/\/doi.org\/10.1021\/acschemneuro.9b00493.","journal-title":"ACS Chem Neurosci"},{"key":"1044_CR66","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","volume":"45","author":"MW Meinhardt","year":"2020","unstructured":"Meinhardt MW, G\u00fcng\u00f6r C, Skorodumov I, Mertens LJ, Spanagel R. Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse. Neuropsychopharmacology. 2020;45:1316\u201322. https:\/\/doi.org\/10.1038\/s41386-020-0694-z.","journal-title":"Neuropsychopharmacology"},{"key":"1044_CR67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1037\/pha0000253","volume":"27","author":"F Sakloth","year":"2019","unstructured":"Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS. Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Exp Clin Psychopharmacol. 2019;27:215\u201326. https:\/\/doi.org\/10.1037\/pha0000253.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1044_CR68","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00213-003-1687-4","volume":"172","author":"JA Harvey","year":"2004","unstructured":"Harvey JA, Quinn JL, Liu R, Aloyo VJ, Romano AG. Selective remodeling of rabbit frontal cortex: relationship between 5-HT2A receptor density and associative learning. Psychopharmacology. 2004;172:435\u201342. https:\/\/doi.org\/10.1007\/s00213-003-1687-4.","journal-title":"Psychopharmacology"},{"key":"1044_CR69","doi-asserted-by":"publisher","unstructured":"Romano AG, Quinn JL, Li L, Dave KD, Schindler EA, Aloyo VJ, et al. Intrahippocampal LSD accelerates learning and desensitizes the 5-HT2A receptor in the rabbit, Romano et al. Psychopharmacologia. 2010;212:441\u20138. https:\/\/doi.org\/10.1007\/s00213-010-2004-7.","DOI":"10.1007\/s00213-010-2004-7"},{"key":"1044_CR70","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0091-3057(97)00436-X","volume":"59","author":"SE Welsh","year":"1998","unstructured":"Welsh SE, Kachelries WJ, Romano AG, Simansky KJ, Harvey JA. Effects of LSD, ritanserin, 8-OH-DPAT, and lisuride on classical conditioning in the rabbit. Pharmacol Biochem Behav. 1998;59:469\u201375. https:\/\/doi.org\/10.1016\/S0091-3057(97)00436-X.","journal-title":"Pharmacol Biochem Behav"},{"key":"1044_CR71","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0091-3057(96)00469-8","volume":"57","author":"DL Frederick","year":"1997","unstructured":"Frederick DL, Gillam MP, Lensing S, Paule MG. Acute effects of LSD on rhesus monkey operant test battery performance. Pharmacol Biochem Behav. 1997;57:633\u201341. https:\/\/doi.org\/10.1016\/S0091-3057(96)00469-8.","journal-title":"Pharmacol Biochem Behav"},{"key":"1044_CR72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00008877-199807000-00002","volume":"9","author":"GG Kinney","year":"1998","unstructured":"Kinney GG, Griffith JC, Hudzik TJ. Antidepressant-like effects of 5-hydroxytryptamine1A receptor agonists on operant responding under a response duration differentiation schedule. Behav Pharmacol. 1998;9:309\u201318.","journal-title":"Behav Pharmacol"},{"key":"1044_CR73","doi-asserted-by":"crossref","unstructured":"Prus AJ, James JR, Rosecrans JA. Conditioned place preference. In: Buccafusco JJ, editor. Methods of behavior analysis in neuroscience. 2nd ed., Boca Raton: CRC Press\/Taylor & Francis; 2009.","DOI":"10.1201\/NOE1420052343.ch4"},{"key":"1044_CR74","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0091-3057(79)90019-4","volume":"11","author":"RJ Katz","year":"1979","unstructured":"Katz RJ, Gormezano G. A rapid and inexpensive technique for assessing the reinforcing effects of opiate drugs. Pharmacol Biochem Behav. 1979;11:231\u20133. https:\/\/doi.org\/10.1016\/0091-3057(79)90019-4.","journal-title":"Pharmacol Biochem Behav"},{"key":"1044_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF00427782","volume":"82","author":"RF Mucha","year":"1984","unstructured":"Mucha RF, Iversen SD. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology. 1984;82:241\u20137. https:\/\/doi.org\/10.1007\/BF00427782.","journal-title":"Psychopharmacology"},{"key":"1044_CR76","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3758\/BF03332869","volume":"4","author":"NA Rossi","year":"1976","unstructured":"Rossi NA, Reid LD. Affective states associated with morphine injections. Psychobiology. 1976;4:269\u201374. https:\/\/doi.org\/10.3758\/BF03332869.","journal-title":"Psychobiology"},{"key":"1044_CR77","doi-asserted-by":"publisher","unstructured":"Grill HJ, Norgren R. The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 1978;143:263\u201379. https:\/\/doi.org\/10.1016\/0006-8993(78)90568-1.","DOI":"10.1016\/0006-8993(78)90568-1"},{"key":"1044_CR78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0893-133X(01)00303-7","volume":"26","author":"Y Itzhak","year":"2002","unstructured":"Itzhak Y, Martin JL. Cocaine-induced conditioned place preference in mice: induction, extinction and reinstatement by related psychostimulants. Neuropsychopharmacol. 2002;26:130\u20134. https:\/\/doi.org\/10.1016\/S0893-133X(01)00303-7.","journal-title":"Neuropsychopharmacol"},{"key":"1044_CR79","doi-asserted-by":"publisher","unstructured":"Hoffman KL. 2 - What can animal models tell us about depressive disorders? In: Hoffman KL, editor. Modeling neuropsychiatric disorders in laboratory animals. Woodhead Publishing; 2016, p. 35\u201386. https:\/\/doi.org\/10.1016\/B978-0-08-100099-1.00002-9.","DOI":"10.1016\/B978-0-08-100099-1.00002-9"},{"key":"1044_CR80","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/BF00187257","volume":"93","author":"P Willner","year":"1987","unstructured":"Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology. 1987;93:358\u201364. https:\/\/doi.org\/10.1007\/BF00187257.","journal-title":"Psychopharmacology"},{"key":"1044_CR81","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1126\/science.138.3536.33","volume":"138","author":"I Gormezano","year":"1962","unstructured":"Gormezano I, Schneiderman N, Deaux E, Fuentes I. Nictitating membrane: classical conditioning and extinction in the albino rabbit. Science. 1962;138:33\u20134. https:\/\/doi.org\/10.1126\/science.138.3536.33.","journal-title":"Science"},{"key":"1044_CR82","doi-asserted-by":"crossref","unstructured":"Greer TL, Thompson LT. Eyeblink conditioning in psychiatric conditions\u2014state of the field and future directions. Frontiers Media SA; 2017.","DOI":"10.3389\/978-2-88945-275-0"},{"key":"1044_CR83","doi-asserted-by":"publisher","unstructured":"Bracha V, Zbarska S, Parker K, Carrel A, Zenitsky G, Bloedel JR. The cerebellum and eyeblink conditioning: learning vs. network performance hypotheses. Neuroscience. 2009;162:787. https:\/\/doi.org\/10.1016\/j.neuroscience.2008.12.042.","DOI":"10.1016\/j.neuroscience.2008.12.042"},{"key":"1044_CR84","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1126\/science.3738519","volume":"233","author":"RF Thompson","year":"1986","unstructured":"Thompson RF. The neurobiology of learning and memory. Science. 1986;233:941\u20137. https:\/\/doi.org\/10.1126\/science.3738519.","journal-title":"Science"},{"key":"1044_CR85","doi-asserted-by":"publisher","unstructured":"Weiss C, Disterhoft JF. Cognitive neuroscience. In: Kempf-Leonard K, editor. Encyclopedia of social measurement, New York: Elsevier; 2005, p. 341\u20139. https:\/\/doi.org\/10.1016\/B0-12-369398-5\/00539-9.","DOI":"10.1016\/B0-12-369398-5\/00539-9"},{"key":"1044_CR86","doi-asserted-by":"publisher","unstructured":"Foerde K. Implicit learning and memory: psychological and neural aspects. In: Koob GF, Moal ML, Thompson RF, editors. Encyclopedia of behavioral neuroscience. Oxford: Academic Press; 2010, p. 84\u201393. https:\/\/doi.org\/10.1016\/B978-0-08-045396-5.00139-1.","DOI":"10.1016\/B978-0-08-045396-5.00139-1"},{"key":"1044_CR87","doi-asserted-by":"publisher","unstructured":"Christian KM, Thompson RF. Eyeblink conditioning. In: Squire LR, editor. Encyclopedia of neuroscience. Oxford: Academic Press; 2009, p. 185\u201392. https:\/\/doi.org\/10.1016\/B978-008045046-9.01310-3.","DOI":"10.1016\/B978-008045046-9.01310-3"},{"key":"1044_CR88","unstructured":"Pavlovian conditioning. National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/units\/paradigms\/151172. Accessed 10 Sep 2023."},{"key":"1044_CR89","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3389\/fphar.2018.00994","volume":"9","author":"K Alper","year":"2018","unstructured":"Alper K, Dong B, Shah R, Sershen H, Vinod KY. LSD administered as a single dose reduces alcohol consumption in C57BL\/6J mice. Front Pharmacol. 2018;9:994. https:\/\/doi.org\/10.3389\/fphar.2018.00994.","journal-title":"Front Pharmacol"},{"key":"1044_CR90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0010-0277(94)90018-3","volume":"50","author":"A Bechara","year":"1994","unstructured":"Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition. 1994;50:7\u201315. https:\/\/doi.org\/10.1016\/0010-0277(94)90018-3.","journal-title":"Cognition"},{"key":"1044_CR91","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1126\/science.1102941","volume":"306","author":"MJ Frank","year":"2004","unstructured":"Frank MJ, Seeberger LC, O\u2019Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science. 2004;306:1940\u20133. https:\/\/doi.org\/10.1126\/science.1102941.","journal-title":"Science"},{"key":"1044_CR92","unstructured":"Reward (probability). National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/reward-probability. Accessed 15 Sep 2023."},{"key":"1044_CR93","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1037\/h0058775","volume":"47","author":"J Olds","year":"1954","unstructured":"Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol. 1954;47:419\u201327. https:\/\/doi.org\/10.1037\/h0058775.","journal-title":"J Comp Physiol Psychol"},{"key":"1044_CR94","doi-asserted-by":"publisher","unstructured":"Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD. The mouse forced swim test. J Vis Exp. 2012:3638. https:\/\/doi.org\/10.3791\/3638.","DOI":"10.3791\/3638"},{"key":"1044_CR95","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nprot.2012.044","volume":"7","author":"DA Slattery","year":"2012","unstructured":"Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc. 2012;7:1009\u201314. https:\/\/doi.org\/10.1038\/nprot.2012.044.","journal-title":"Nat Protoc"},{"key":"1044_CR96","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cub.2022.02.034","volume":"32","author":"NK Smith","year":"2022","unstructured":"Smith NK, Plotkin JM, Grueter BA. Hunger dampens a nucleus accumbens circuit to drive persistent food seeking. Curr Biol. 2022;32:1689-1702.e4. https:\/\/doi.org\/10.1016\/j.cub.2022.02.034.","journal-title":"Curr Biol"},{"key":"1044_CR97","doi-asserted-by":"publisher","first-page":"247","DOI":"10.31887\/DCNS.2017.19.3\/rspanagel","volume":"19","author":"R Spanagel","year":"2017","unstructured":"Spanagel R. Animal models of addiction. Dialog Clin Neurosci. 2017;19:247\u201358.","journal-title":"Dialog Clin Neurosci"},{"key":"1044_CR98","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/00221309.1937.9917951","volume":"16","author":"BF Skinner","year":"1937","unstructured":"Skinner BF. Two types of conditioned reflex: a reply to Miller and Konorski. J Gen Psychol. 1937;16:272\u20139. https:\/\/doi.org\/10.1080\/00221309.1937.9917951.","journal-title":"J Gen Psychol"},{"key":"1044_CR99","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.psych.54.101601.145124","volume":"54","author":"JER Staddon","year":"2003","unstructured":"Staddon JER, Cerutti DT. Operant conditioning. Annu Rev Psychol. 2003;54:115\u201344. https:\/\/doi.org\/10.1146\/annurev.psych.54.101601.145124.","journal-title":"Annu Rev Psychol"},{"key":"1044_CR100","unstructured":"NIMH\u202f\u00bb Subconstruct: Effort n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/effort.shtml. Accessed 15 Apr 2021."},{"key":"1044_CR101","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.paid.2015.02.029","volume":"80","author":"LE Taubitz","year":"2015","unstructured":"Taubitz LE, Pedersen WS, Larson CL. BAS reward responsiveness: a unique predictor of positive psychological functioning. Personal Individ Differ. 2015;80:107\u201312. https:\/\/doi.org\/10.1016\/j.paid.2015.02.029.","journal-title":"Personal Individ Differ"},{"key":"1044_CR102","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1176\/appi.ajp.2018.17101124","volume":"175","author":"H Keren","year":"2018","unstructured":"Keren H, O\u2019Callaghan G, Vidal-Ribas P, Buzzell GA, Brotman MA, Leibenluft E, et al. Reward processing in depression: a conceptual and meta-analytic review across fMRI and EEG studies. Am J Psychiatry. 2018;175:1111\u201320. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17101124.","journal-title":"Am J Psychiatry"},{"key":"1044_CR103","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.biopsych.2013.10.026","volume":"76","author":"J Downar","year":"2014","unstructured":"Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014;76:176\u201385. https:\/\/doi.org\/10.1016\/j.biopsych.2013.10.026.","journal-title":"Biol Psychiatry"},{"key":"1044_CR104","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1034\/j.1600-0447.2001.103002122.x","volume":"103","author":"J Spijker","year":"2001","unstructured":"Spijker J, Bijl RV, de Graaf R, Nolen WA. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand. 2001;103:122\u201330. https:\/\/doi.org\/10.1034\/j.1600-0447.2001.103002122.x.","journal-title":"Acta Psychiatr Scand"},{"key":"1044_CR105","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1176\/appi.ajp.2020.20010094","volume":"178","author":"SL Sequeira","year":"2021","unstructured":"Sequeira SL, Silk JS, Ladouceur CD, Hanson JL, Ryan ND, Morgan JK, et al. Association of neural reward circuitry function with response to psychotherapy in youths with anxiety disorders. Am J Psychiatry. 2021;178:343\u201351. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20010094.","journal-title":"Am J Psychiatry"},{"key":"1044_CR106","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1017\/S0033291715002901","volume":"46","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:1379\u201390. https:\/\/doi.org\/10.1017\/S0033291715002901.","journal-title":"Psychol Med"},{"key":"1044_CR107","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","volume":"113","author":"JS Aday","year":"2020","unstructured":"Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: a systematic review. Neurosci Biobehav Rev. 2020;113:179\u201389. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.03.017.","journal-title":"Neurosci Biobehav Rev"},{"key":"1044_CR108","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont\u00e9 KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:155\u201366. https:\/\/doi.org\/10.1177\/0269881119897615.","journal-title":"J Psychopharmacol"},{"key":"1044_CR109","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513\u201320. https:\/\/doi.org\/10.1097\/NMD.0000000000000113.","journal-title":"J Nerv Ment Dis"},{"key":"1044_CR110","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29:57\u201368. https:\/\/doi.org\/10.1177\/0269881114555249.","journal-title":"J Psychopharmacol"},{"key":"1044_CR111","doi-asserted-by":"crossref","unstructured":"Cavarra M, Falzone A, Ramaekers JG, Kuypers KPC, Mento C. Psychedelic-assisted psychotherapy\u2014a systematic review of associated psychological interventions. Front Psychol. 2022;13.","DOI":"10.3389\/fpsyg.2022.887255"},{"key":"1044_CR112","doi-asserted-by":"publisher","unstructured":"Schenberg EE. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.00733.","DOI":"10.3389\/fphar.2018.00733"},{"key":"1044_CR113","unstructured":"Leysen JE, Niemegeers CJ, Van Nueten JM, Laduron PM. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol. 1982;21:301\u201314."},{"key":"1044_CR114","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","volume":"72","author":"M Kometer","year":"2012","unstructured":"Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72:898\u2013906. https:\/\/doi.org\/10.1016\/j.biopsych.2012.04.005.","journal-title":"Biol Psychiatry"},{"key":"1044_CR115","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/ijnp\/pyy011","volume":"21","author":"MG Bossong","year":"2018","unstructured":"Bossong MG, Wilson R, Appiah-Kusi E, McGuire P, Bhattacharyya S. Human striatal response to reward anticipation linked to hippocampal glutamate levels. Int J Neuropsychopharmacol. 2018;21:623\u201330. https:\/\/doi.org\/10.1093\/ijnp\/pyy011.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1044_CR116","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","volume":"68","author":"ES Bromberg-Martin","year":"2010","unstructured":"Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron. 2010;68:815\u201334. https:\/\/doi.org\/10.1016\/j.neuron.2010.11.022.","journal-title":"Neuron"},{"key":"1044_CR117","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:2214. https:\/\/doi.org\/10.1038\/s41598-020-59282-y.","journal-title":"Sci Rep"},{"key":"1044_CR118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","volume":"15","author":"AK Davis","year":"2020","unstructured":"Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020;15:39\u201345. https:\/\/doi.org\/10.1016\/j.jcbs.2019.11.004.","journal-title":"J Contextual Behav Sci"},{"key":"1044_CR119","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.022.","journal-title":"Cell Rep"},{"key":"1044_CR120","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday JS, Davis AK, Mitzkovitz CM, Bloesch EK, Davoli CC. Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci. 2021;4:424\u201335. https:\/\/doi.org\/10.1021\/acsptsci.1c00014.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1044_CR121","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725\u201331. https:\/\/doi.org\/10.1177\/0269881118754710.","journal-title":"J Psychopharmacol"},{"key":"1044_CR122","doi-asserted-by":"crossref","unstructured":"Roseman L, Preller KH, Fotiou E, Winkelman MJ. Editorial: Psychedelic sociality: pharmacological and extrapharmacological perspectives. Front Pharmacol. 2022;13.","DOI":"10.3389\/fphar.2022.979764"},{"key":"1044_CR123","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fpsyg.2017.01238","volume":"8","author":"FS Barrett","year":"2017","unstructured":"Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR. Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Front Psychol. 2017;8:1238. https:\/\/doi.org\/10.3389\/fpsyg.2017.01238.","journal-title":"Front Psychol"},{"key":"1044_CR124","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","volume":"232","author":"M Kaelen","year":"2015","unstructured":"Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, et al. LSD enhances the emotional response to music. Psychopharmacology. 2015;232:3607\u201314. https:\/\/doi.org\/10.1007\/s00213-015-4014-y.","journal-title":"Psychopharmacology"},{"key":"1044_CR125","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/lm.60803","volume":"10","author":"JA Harvey","year":"2003","unstructured":"Harvey JA. Role of the serotonin 5-HT2A receptor in learning. Learn Mem. 2003;10:355\u201362. https:\/\/doi.org\/10.1101\/lm.60803.","journal-title":"Learn Mem"},{"key":"1044_CR126","doi-asserted-by":"publisher","first-page":"E1382","DOI":"10.1073\/pnas.1525586113","volume":"113","author":"A Barre","year":"2016","unstructured":"Barre A, Berthoux C, De Bundel D, Valjent E, Bockaert J, Marin P, et al. Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning. Proc Natl Acad Sci. 2016;113:E1382\u201391. https:\/\/doi.org\/10.1073\/pnas.1525586113.","journal-title":"Proc Natl Acad Sci"},{"key":"1044_CR127","unstructured":"Habit - Sensorimotor. National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/habit-sensorimotor. Accessed 22 Sep 2023."},{"key":"1044_CR128","unstructured":"Negative Valence Systems. National Institute of Mental Health (NIMH) n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/negative-valence-systems. Accessed 9 Jan 2022."},{"key":"1044_CR129","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.copsyc.2014.12.011","volume":"4","author":"R Admon","year":"2015","unstructured":"Admon R, Pizzagalli DA. Dysfunctional reward processing in depression. Curr Opin Psychol. 2015;4:114\u20138. https:\/\/doi.org\/10.1016\/j.copsyc.2014.12.011.","journal-title":"Curr Opin Psychol"},{"key":"1044_CR130","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jamapsychiatry.2020.2139","volume":"77","author":"DC Halahakoon","year":"2020","unstructured":"Halahakoon DC, Kieslich K, O\u2019Driscoll C, Nair A, Lewis G, Roiser JP. Reward-processing behavior in depressed participants relative to healthy volunteers: a systematic review and meta-analysis. JAMA Psychiat. 2020;77:1286\u201395. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.2139.","journal-title":"JAMA Psychiat"},{"key":"1044_CR131","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuron.2013.04.008","volume":"78","author":"D Lee","year":"2013","unstructured":"Lee D. Decision making: from neuroscience to psychiatry. Neuron. 2013;78:233\u201348. https:\/\/doi.org\/10.1016\/j.neuron.2013.04.008.","journal-title":"Neuron"},{"key":"1044_CR132","doi-asserted-by":"publisher","unstructured":"Yip SW, Wei Zhai Z, Balodis IM, Potenza MN. Positive Mood States and Gambling Disorder. In: Gruber J, editor. The Oxford handbook of positive emotion and psychopathology, Oxford University Press; 2019. https:\/\/doi.org\/10.1093\/oxfordhb\/9780190653200.013.24.","DOI":"10.1093\/oxfordhb\/9780190653200.013.24"},{"key":"1044_CR133","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/npp.2010.165","volume":"36","author":"RD Rogers","year":"2011","unstructured":"Rogers RD. The roles of dopamine and serotonin in decision making: evidence from pharmacological experiments in humans. Neuropsychopharmacol. 2011;36:114\u201332. https:\/\/doi.org\/10.1038\/npp.2010.165.","journal-title":"Neuropsychopharmacol"},{"key":"1044_CR134","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1038\/s41598-022-14165-2","volume":"12","author":"M Hibicke","year":"2022","unstructured":"Hibicke M, Nichols CD. Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies. Sci Rep. 2022;12:10019. https:\/\/doi.org\/10.1038\/s41598-022-14165-2.","journal-title":"Sci Rep"},{"key":"1044_CR135","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00213-010-1887-7","volume":"213","author":"V Katsidoni","year":"2011","unstructured":"Katsidoni V, Apazoglou K, Panagis G. Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacology. 2011;213:337\u201354. https:\/\/doi.org\/10.1007\/s00213-010-1887-7.","journal-title":"Psychopharmacology"},{"key":"1044_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2022.109220","volume":"218","author":"JE Henningfield","year":"2022","unstructured":"Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, et al. Psychedelic drug abuse potential assessment research for new drug applications and controlled substances act scheduling. Neuropharmacology. 2022;218:1\u201319. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109220.","journal-title":"Neuropharmacology"},{"key":"1044_CR137","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983\u201392. https:\/\/doi.org\/10.1177\/0269881114548296.","journal-title":"J Psychopharmacol"},{"key":"1044_CR138","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43:55\u201360. https:\/\/doi.org\/10.3109\/00952990.2016.1170135.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1044_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01656-7","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Anderson BT. Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacol. 2023. https:\/\/doi.org\/10.1038\/s41386-023-01656-7.","journal-title":"Neuropsychopharmacol"},{"key":"1044_CR140","unstructured":"Reeves B, Deeks, Higgins J, Shea, Tugwell P, Wells G. Chapter 24: Including non-randomized studies on intervention effects in Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. https:\/\/training.cochrane.org\/handbook\/current\/chapter-24. Accessed 17 May 2022."},{"key":"1044_CR141","unstructured":"NIMH\u202f\u00bb Reward Anticipation n.d. https:\/\/www.nimh.nih.gov\/research\/research-funded-by-nimh\/rdoc\/constructs\/reward-anticipation#paradigm_472. Accessed 14 Jan 2023."},{"key":"1044_CR142","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1002\/hbm.25174","volume":"41","author":"L Smigielski","year":"2020","unstructured":"Smigielski L, Kometer M, Scheidegger M, Stress C, Preller KH, Koenig T, et al. P300-mediated modulations in self\u2013other processing under psychedelic psilocybin are related to connectedness and changed meaning: a window into the self\u2013other overlap. Hum Brain Mapp. 2020;41:4982\u201396. https:\/\/doi.org\/10.1002\/hbm.25174.","journal-title":"Hum Brain Mapp"},{"key":"1044_CR143","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiat. 2015;78:544\u201353. https:\/\/doi.org\/10.1016\/j.biopsych.2014.11.015.","journal-title":"Biol Psychiat"},{"key":"1044_CR144","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-016-4453-0","volume":"234","author":"ME Liechti","year":"2017","unstructured":"Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology. 2017;234:1499\u2013510. https:\/\/doi.org\/10.1007\/s00213-016-4453-0.","journal-title":"Psychopharmacology"},{"key":"1044_CR145","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol. 2016;26:1043\u201350. https:\/\/doi.org\/10.1016\/j.cub.2016.02.010.","journal-title":"Curr Biol"},{"key":"1044_CR146","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s00213-017-4610-0","volume":"234","author":"R Kraehenmann","year":"2017","unstructured":"Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology. 2017;234:2031\u201346. https:\/\/doi.org\/10.1007\/s00213-017-4610-0.","journal-title":"Psychopharmacology"},{"key":"1044_CR147","doi-asserted-by":"publisher","DOI":"10.1111\/psyp.13822","author":"S Olbrich","year":"2021","unstructured":"Olbrich S, Preller KH, Vollenweider FX. Lsd and ketanserin and their impact on the human autonomic nervous system. Psychophysiology. 2021. https:\/\/doi.org\/10.1111\/psyp.13822.","journal-title":"Psychophysiology"},{"key":"1044_CR148","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, M\u00fcller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45:462\u201371. https:\/\/doi.org\/10.1038\/s41386-019-0569-3.","journal-title":"Neuropsychopharmacology"},{"key":"1044_CR149","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721002531","author":"I Wie\u00dfner","year":"2021","unstructured":"Wie\u00dfner I, Falchi M, Palhano-Fontes F, Feilding A, Ribeiro S, T\u00f3foli LF. LSD, madness and healing: mystical experiences as possible link between psychosis model and therapy model. Psychol Med. 2021. https:\/\/doi.org\/10.1017\/S0033291721002531.","journal-title":"Psychol Med"},{"key":"1044_CR150","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13143","volume":"27","author":"H de Wit","year":"2022","unstructured":"de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: a placebo-controlled, dose\u2013response study. Addict Biol. 2022;27: e13143. https:\/\/doi.org\/10.1111\/adb.13143.","journal-title":"Addict Biol"},{"key":"1044_CR151","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, M\u00fcller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacol. 2016;41:2638\u201346. https:\/\/doi.org\/10.1038\/npp.2016.82.","journal-title":"Neuropsychopharmacol"},{"key":"1044_CR152","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","volume":"235","author":"Y Schmid","year":"2018","unstructured":"Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 2018;235:535\u201345. https:\/\/doi.org\/10.1007\/s00213-017-4733-3.","journal-title":"Psychopharmacology"},{"key":"1044_CR153","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/0269881114542454","volume":"28","author":"Y Schmid","year":"2014","unstructured":"Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME. Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol. 2014;28:847\u201356. https:\/\/doi.org\/10.1177\/0269881114542454.","journal-title":"J Psychopharmacol"},{"key":"1044_CR154","volume-title":"LSD: R\u00fcckkehr in die klinische Forschung: Mystik, Salutogenese","author":"MK Diesch","year":"2015","unstructured":"Diesch MK. LSD: R\u00fcckkehr in die klinische Forschung: Mystik, Salutogenese. Psychotherapie: Nachtschatten-Verlag; 2015."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01044-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T20:20:45Z","timestamp":1701980445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":154,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01044-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"16 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NP was employed as the responsible pharmacist at Aracell Zist Darou Pharmaceutical but has received no funding, financial, or infrastructure support for this project from Aracell Zist Darou Pharmaceutical. RSM has received research grant support from CIHR\/GACD\/Chinese National Natural Research Foundation; speaker\/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. RSM is a CEO of Braxia Scientific Corp. MS works part-time as CMO for Reconnect Labs, an academic spin-off drug development company that he co-founded in 2021.The rest of the authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 statement (conflicts of interest)"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding resources"}},{"value":"NP and RSM developed the idea of the RDoC-based framework for the review. NP designed the methodology for screening, data categorization and tabulation. NP, AK, and FYS carried out the screening. NP and FYS prepared the visualizations. FYS and AK performed the risk of bias assessment. JDM provided context and expertise for interpreting the preclinical studies. NP and FYS wrote the paper.NP, FYS, MS, and JDM edited and revised the paper. All authors viewed and approved the final manuscript and had the opportunity to comment on earlier drafts and agree to be accountable for the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}